SynteractHCR Expands Senior Management Team with Appointment of Etienne Drouet as Vice President, Strategic Development
SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development.
SAN DIEGO – Feb. 26, 2015 –SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development. This is a new position created to augment the depth of the company’s oncology and complex trial expertise. Adding experience to an already capable senior management team brings new perspectives and enhances the team’s skills as this global CRO continues its focus on the small and mid-size biopharma segment.
Etienne Drouet has more than 20 years of experience in executive leadership, program and project management, clinical trial management, and research and development within the contract research and biopharmaceutical industries. At SynteractHCR he will join the senior management team, helping to develop company strategy and business models. His primary objective will be to ensure excellence in operational delivery to clients. He will report directly to CEO Wendel Barr.
“Since we work with smaller and mid-sized companies on complex global trials, integrating his extensive drug development knowledge is key to further improving both the strategic thinking and executional support our clients request,” said Wendel Barr, CEO of SynteractHCR. “We are delighted to have him on board the team.”
Mr. Drouet joins SynteractHCR from Premier Research where he was executive director, global oncology. Previously he was a program manager and senior project manager at ICON; held project management positions at AAI Pharma, and Cvitkovic and Associés Consultants; was a senior CRA at the Breast Cancer International Research Group; and a research scientist with Sanofi Aventis. Drouet has notable therapeutic experience in solid tumor and hematological cancers as well as CNS (central nervous systems).
He has an engineering degree in Biotechnology from the European School of Biotechnology in Strasbourg. Etienne Drouet also holds a Master in Science with a major in Cell Biology, Molecular Genetics, and Virology from the University Louis Pasteur in Strasbourg, Alsace, France.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
